Sunday, August 31, 2014

Novartis apologizes for not disclosing side-effects of leukemia drugs sooner

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.

Credit: Reuters/Arnd Wiegmann

Related Topics Health » Japan »

TOKYO (Reuters) - The Japanese unit of Novartis AG apologized on Thursday for failing to report to authorities in a timely manner side-effects of its leukemia drugs, in the company's latest scandal in the country.

Novartis Pharma KK, the Swiss drugmaker's wholly owned local subsidiary, said Japan's Ministry of Health, Labour and Welfare ordered the company to improve its practices after the company did not report side-effects of its Gleevec and Tasigna leukemia treatments until around April.

The ministry said serious side-effects must be reported within a month of discovery. Media reports said such side-effects had been known between April 2013 and January 2014.

"We deeply regret that we have allowed this situation to arise, and offer our deepest apologies to our patients, their families, medical professionals, as well as the public," the company said in a statement.

"We take it very seriously, that side-effects, which should be extremely important to any pharmaceutical company, were not reported appropriately."

Earlier in July, Tokyo prosecutors said they would charge the unit and a former employee in connection with allegations of data manipulation to promote its best-selling blood pressure drug Diovan.

The prosecutors office in June arrested Nobuo Shiraishi on allegations that he gave false data to researchers whose work was used for advertising.

(Reporting by Ritsuko Ando; Editing by Chris Gallagher and Ryan Woo)

FILED UNDER: HealthJapan Tweet this Link this Share this Digg this EmailPrintReprints   We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see (0)Be the first to comment on Add yours using the box above.
#most-popular .module

View the Original article

No comments:

Post a Comment